Detection of ADAM15 in urine from patients with bladder cancer.
ADAM15
Bladder cancer
Proteolytic activity
Journal
Analytical biochemistry
ISSN: 1096-0309
Titre abrégé: Anal Biochem
Pays: United States
ID NLM: 0370535
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
received:
08
04
2022
revised:
04
07
2022
accepted:
04
07
2022
pubmed:
11
7
2022
medline:
24
8
2022
entrez:
10
7
2022
Statut:
ppublish
Résumé
Cancer is one of the leading causes of death in the United States and Europe. Of the cancers, bladder cancer is the 10th most frequently diagnosed cancer and the 13th most frequently diagnosed cancer in men. There are many studies showing that proteolytic enzymes, e.g. A Disintegrin and Metalloproteinases (ADAMs), play a key role in the development and progression of neoplasms. In this paper, we present the use of chromogenic substrate of ADAM15 for the qualitative determination of specific activity of enzyme in urine of patients with confirmed bladder cancer. In the first step, we optimized the substrate molecule in non-primed positions using combinatorial chemistry. By means of the obtained ABZ-His-Ala-Arg-Gly-ANB-NH
Identifiants
pubmed: 35810783
pii: S0003-2697(22)00261-5
doi: 10.1016/j.ab.2022.114805
pii:
doi:
Substances chimiques
Membrane Proteins
0
Peptides
0
ADAM Proteins
EC 3.4.24.-
ADAM15 protein, human
EC 3.4.24.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114805Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.